Last reviewed · How we verify

Lidocaine jelly application

Keimyung University Dongsan Medical Center · FDA-approved active Small molecule

Lidocaine jelly is a topical local anesthetic that blocks sodium channels in nerve cell membranes to prevent pain signal transmission.

Lidocaine jelly is a topical local anesthetic that blocks sodium channels in nerve cell membranes to prevent pain signal transmission. Used for Topical anesthesia for minor procedures and pain relief, Urological procedures, Wound care and minor surgical applications.

At a glance

Generic nameLidocaine jelly application
SponsorKeimyung University Dongsan Medical Center
Drug classLocal anesthetic
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaPain management / Anesthesia
PhaseFDA-approved

Mechanism of action

Lidocaine is an amide-type local anesthetic that reversibly inhibits sodium influx into nerve fibers, thereby preventing depolarization and conduction of action potentials. When applied as a jelly formulation, it provides localized anesthesia at the site of application, numbing tissues without systemic absorption when used appropriately. This allows for pain-free procedures or relief of localized pain and discomfort.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: